Fig. 2: Continuous olaparib combined with RT (COM) significantly downregulates EIF4E2 in SCLC. | Nature Communications

Fig. 2: Continuous olaparib combined with RT (COM) significantly downregulates EIF4E2 in SCLC.

From: PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer

Fig. 2

a Heatmap showing hierarchical clustering of significantly changed genes in SBC5 cells treated with vehicle (VEH), olaparib (OLA), RT, or combination of olaparib and RT (COM) for 3 days. b Top 10 pathways significantly modulated by the COM. The p value was calculated by GESA with two-tailed permutation testing. c Fold change of EIF4 family mRNA level treated with OLA, RT, or COM treatment as normalized by the expression to VEH. d Upper: Quantification of the relative intensity of EIF4E2 protein level normalized by the intensity of β-Actin. Lower: Western blot analysis of EIF4E2 expression in H1048 (P), H446 (N), SBC5 (Y) and KP1 (A) cells treated with vehicle, OLA, RT or COM treatment from one of two independent experiments. e Left: Schematic of KP1 allografts experimental design (n = 5 mice for each treatment, Created in BioRender. Ran, X. (2025) https://BioRender.com/e93s595). Middle: Western blot against EIF4E2 and Actin. Right: Quantification of the relative intensity of EIF4E2 protein level normalized by the intensity of β-Actin (VEH vs COM p = 0.0052, OLA vs COM p = 0.001, RT vs COM p = 0.044). Mean counts are presented as a line and the comparison was calculated with one-way ANOVA. (p: 0.001 < ** < 0.01 < * < 0.05). All exact p values are listed in the source data. Source data are provided as a Source Data file.

Back to article page